prevent
vaccin
launch
edward
jenner
fundament
experi
year
ago
inocul
fluid
cowpox
lesion
protect
eight
yearold
boy
challeng
smallpox
today
vaccin
clearli
one
import
effect
public
health
measur
reduc
impact
virusassoci
infecti
diseas
vaccin
allow
global
erad
smallpox
elimin
poliomyel
europ
prophylact
vaccin
hand
provid
solid
protect
yellow
fever
rabi
measl
mump
rubella
varicella
hepat
b
tick
born
japanes
enceph
inde
worldwid
vaccin
prevent
million
case
measl
influenza
year
despit
great
success
new
efficaci
vaccin
urgent
need
continu
threat
emerg
reemerg
infect
moreov
effort
prevent
treat
import
infecti
diseas
scientif
commun
known
year
mani
old
challeng
remain
decad
avail
influenza
vaccin
help
reduc
morbid
mortal
relat
influenza
viru
infect
howev
influenza
viru
vaccin
still
shortcom
regard
effect
antigen
drift
variant
season
influenza
virus
moreov
vaccin
offer
littl
protect
influenza
virus
novel
subtyp
pandem
potenti
schotsaert
garciasastr
address
limit
compar
mechan
immun
induc
inactiv
influenza
vaccin
live
attenu
influenza
vaccin
trival
inactiv
vaccin
commonli
use
immun
human
popul
season
influenza
recent
quadrival
inactiv
vaccin
use
provid
addit
antigen
differ
influenza
b
viru
ingredi
live
attenu
influenza
viru
vaccin
vaccin
type
intend
mimic
natur
infect
induc
cell
mediat
immun
human
judgement
vaccin
effect
vaccin
individu
howev
still
exclus
base
level
hemagglutininspecif
virusneutr
antibodi
sera
consider
correl
protect
immun
influenza
viru
antigen
addit
hemagglutinin
offer
promis
develop
univers
influenza
vaccin
induc
heterosubtyp
protect
immun
season
potenti
pandem
influenza
virus
recent
past
face
era
emerg
epidem
viru
infect
unpreced
regard
scope
scale
worldwid
impact
major
diseas
burden
human
associ
arthropodborn
flavivirus
includ
dengu
viru
denv
west
nile
viru
wnv
zika
viru
zikv
transmit
mosquito
two
review
glaxosmithklin
vaccin
siena
itali
email
rinorrappuoli
gskcom
rino
rappuoli
chief
scientist
head
extern
r
gsk
vaccin
professor
vaccin
research
imperi
colleg
london
primari
interest
research
develop
bacteri
viral
vaccin
use
innov
technolog
paper
report
statu
quo
vaccin
target
flavivirus
fernandez
diamond
elabor
current
strategi
make
zikv
specif
vaccin
readili
avail
remark
within
short
time
epidem
emerg
zikv
sever
candid
vaccin
creat
advanc
toward
clinic
test
vaccin
base
variou
approach
includ
viral
vector
nucleic
acid
deliveri
common
target
antigen
viral
envelop
protein
prme
induct
protect
humor
immun
zikv
addit
author
detail
complex
develop
zikv
vaccin
context
possibl
crossreact
immun
flavivirus
along
potenti
occurr
syndrom
associ
zikv
infect
epidemiolog
studi
actual
clinic
develop
new
vaccin
proce
discuss
scherwitzl
et
al
differ
option
prevent
vaccin
denv
wnv
zikv
infect
present
focu
candid
vaccin
alreadi
undergo
clinic
evalu
human
substanti
progress
made
denv
vaccin
first
vaccin
licens
variou
dengu
endem
countri
vaccin
candid
reach
phase
iii
clinic
test
okba
et
al
address
particular
vaccin
issu
associ
recent
emerg
middl
east
respiratori
syndrom
coronaviru
merscov
novel
human
coronaviru
caus
diseas
similar
sever
acut
respiratori
syndrom
sar
dromedari
camel
critic
anim
reservoir
respons
spread
viru
human
vaccin
target
primari
zoonot
infect
could
use
camel
select
human
popul
healthcar
worker
person
contact
camel
patient
among
risk
merscov
infect
initi
promis
approach
vaccin
develop
focu
merscov
spike
protein
key
antigen
readili
advanc
clinic
test
human
moreov
increas
knowledg
mechan
protect
immun
merscov
infect
human
anim
result
identifi
morebroadli
effect
immun
respons
develop
prevent
mean
potenti
emerg
coronavirus
particularli
promin
exampl
need
prepared
measur
emerg
infecti
diseas
enorm
intern
effort
obtain
efficaci
vaccin
ebola
viru
respons
larg
outbreak
ebola
viru
diseas
west
africa
sever
experiment
vaccin
rapidli
develop
proceed
clinic
trial
includ
recombin
vesicular
stomat
viru
rvsv
deliv
envelop
glycoprotein
gp
zair
strain
ebola
viru
rvsvzebov
review
paper
medaglini
siegrist
focus
candid
vaccin
first
demonstr
safeti
immunogen
efficaci
clinic
studi
author
discuss
new
option
develop
understand
mechan
underli
protect
immun
induc
rvsvzebov
far
still
limit
data
immunomonitor
vaccin
studi
adult
suggest
import
contribut
gpspecif
antibodi
respons
protect
ebola
viru
diseas
interestingli
result
also
indic
involv
innat
respons
determin
possibl
delic
balanc
vaccineassoci
reactogen
protect
adapt
immun
absenc
continu
ebola
outbreak
applic
modern
technolog
system
biolog
start
studi
avail
serum
sampl
human
innat
adapt
immun
respons
rvsvzebov
vaccin
indepth
analys
correl
data
analysi
gene
express
clinic
observ
immunolog
data
end
integr
studi
may
help
identifi
novel
molecular
biomark
key
immunolog
signatur
predict
safe
protect
rvsvzebov
immun
three
paper
review
virus
human
papillomaviru
hpv
hepat
b
viru
hbv
hepat
c
viru
hcv
evad
innat
immun
mechan
establish
chronic
infect
eventu
may
lead
cancer
case
chronic
infect
establish
immun
system
becom
unabl
mount
effect
immun
respons
usual
unabl
respond
vaccin
review
wembo
et
al
show
case
hpv
success
vaccin
abl
prevent
infect
still
need
vaccin
abl
clear
establish
chronic
infect
observ
establish
lesion
regress
spontan
suggest
mani
case
immun
system
may
abl
mount
effect
respons
therefor
mani
therapeut
vaccin
develop
induc
immun
respons
infect
peopl
vaccin
aim
develop
strong
cellular
respons
usual
target
gene
case
increas
clearanc
observ
million
peopl
chronic
infect
hbv
continu
major
public
health
problem
despit
fact
infect
prevent
recombin
vaccin
deliv
yeastproduc
envelop
protein
hbsag
review
kosinska
et
al
discuss
process
underli
critic
immun
toler
associ
chronic
hbv
infect
hbv
infect
distinct
immun
environ
liver
simultan
produc
massiv
amount
secret
viru
antigen
filament
spheric
particl
addit
infecti
progeni
consequ
mechan
function
delet
toler
virusspecif
cell
respons
suggest
cooper
inhibit
hbv
clearanc
overcom
immun
toler
chronic
hepat
b
therapeut
vaccin
would
highli
desir
variou
approach
followedup
develop
appropri
candid
vaccin
major
hurdl
howev
includ
need
amplifi
virusspecif
effector
cell
immun
privileg
environ
liver
new
candid
vaccin
vaccin
strategi
direct
cell
addit
hbv
antigen
discuss
well
combin
therapeut
vaccin
checkpoint
inhibit
antivir
drug
therapi
overal
new
develop
hold
great
promis
reduc
substanti
diseas
burden
relat
chronic
hbv
infect
case
hcv
chri
walker
tackl
question
whether
still
role
hcv
vaccin
given
success
antivir
hcv
therapi
avail
today
conclus
yet
clear
whether
therapi
go
abl
reduc
global
burden
diseas
therefor
vaccin
develop
pursu
scope
prevent
primari
infect
prevent
reinfect
cure
individu
report
two
prevent
vaccin
develop
one
base
elicit
cell
immun
base
neutral
antibodi
first
one
test
peopl
risk
hcv
infect
second
one
still
preclin
studi
observ
follow
primari
infect
peopl
progress
chronic
infect
other
spontan
resolv
infect
suggest
case
immun
system
effect
clear
infect
therefor
goal
vaccin
necessarili
induc
steril
immun
rather
prevent
establish
chronic
infect
final
chri
walker
ask
question
whether
vaccin
also
develop
peopl
clear
infect
therapi
question
infect
clear
immun
system
regain
abil
respond
vaccin
remain
unabl
respond
vaccin
case
chronic
infect
two
paper
describ
vaccin
cytomegaloviru
cmv
respiratori
syncyti
viru
rsv
nearli
imposs
produc
decad
ago
vaccin
seem
easi
make
thank
understand
engin
antigen
use
structurebas
antigen
design
case
rsv
crystal
structur
f
protein
postfus
conform
first
prefus
conform
later
show
remark
differ
two
structur
allow
engin
antigen
stabil
prefus
conform
use
immun
anim
model
prefus
antigen
shown
induc
tenfold
increas
titer
neutral
antibodi
suggest
antigen
choic
rsv
vaccin
case
cmv
clinic
trial
perform
antigen
gb
adjuv
shown
although
vaccin
induc
protect
infect
good
enough
vaccin
surpris
came
found
potent
neutral
antibodi
cmv
recogn
gb
complex
structur
compos
protein
today
known
pentam
find
gave
insight
mechan
cmv
entri
mammalian
cell
aid
develop
new
potent
antigen
develop
vaccin
pentamer
shown
use
viru
enter
epitheli
cell
complex
ghglgo
use
enter
fibroblast
today
pentam
express
mammalian
cell
shown
induc
potent
neutral
antibodi
seem
antigen
choic
cmv
vaccin
vaccin
probabl
efficaci
public
health
tool
centuri
greatli
reduc
morbid
mortal
viral
diseas
across
globe
today
vaccin
viral
diseas
move
confront
challeng
emerg
infect
caus
pathogen
littl
known
biolog
associ
unpredict
impact
societi
moreov
field
still
need
address
massiv
diseas
burden
chronic
infect
caus
virus
alreadi
know
trick
effici
evad
human
immun
system
new
insight
immun
correl
protect
viral
diseas
vaccin
prerequisit
ration
induct
safe
broadli
protect
immun
respons
offer
promis
chanc
highli
innov
vaccin
develop
import
aim
includ
avail
vaccin
rapidli
produc
deliv
provid
protect
emerg
reemerg
virus
induct
potent
balanc
innat
respons
upon
vaccin
hold
great
promis
overcom
malfunct
immun
defens
chronic
infect
recent
advanc
vaccin
research
demonstr
feasibl
test
wide
rang
candid
vaccin
includ
genet
engin
live
virus
preclin
proofofprincipl
studi
clinic
trial
human
